deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT02573935

Clarithromycin in Multiple Myeloma Induction Therapy (CLAIM)

A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma

Sponsor: Danish Myeloma Study Group

Conditions Multiple Myeloma
Interventions Clarithromycin Placebo VCD induction therapy
Updated 10 times since 2017 Last updated: Sep 19, 2016 Started: Jan 31, 2015 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone)

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

A PHASE2 clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by Danish Myeloma Study Group and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotTerminated~Aug 2017 – ~May 2018 · 9 months · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotTerminated~Jun 2019 – ~Nov 2020 · 17 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 23 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 5 earlier versions

  1. Jun 2019 — Nov 2020 [monthly]

    Terminated PHASE2

  2. Jun 2018 — Jun 2019 [monthly]

    Terminated PHASE2

  3. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  4. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Aug 2017 [monthly]

    Terminated PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Danish Myeloma Study Group
  • Henrik Gregersen
Data source: Aalborg University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations